- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01.10. | Takeda, in reversal, abandons cell therapy research | ||
| 01.10. | The top biopharma conferences in 2026 | ||
| 01.10. | A new biotech aims to get RNA drugs into the brain | ||
| 01.10. | As shutdown begins, FDA to stop accepting new drug submissions | ||
| 01.10. | FDA official's comments spark Aurinia sell-off; Halozyme buys a biotech | ||
| 30.09. | Trump, Pfizer drug pricing deal short on details, possible impact | ||
| 30.09. | Metsera strengthens case for Pfizer buyout with latest study data | ||
| 30.09. | Crystalys debuts with $205M and plans for a better gout drug | ||
| 30.09. | Star raises another $125M for its blood disease drug | ||
| 29.09. | Emma Walmsley, big pharma's first female CEO, to depart GSK | ||
| 29.09. | Genmab to acquire closely watched cancer drug in $8B Merus buyout | ||
| 29.09. | Moonlake shares crash on mixed study results for immune drug | ||
| 29.09. | Softgel and lipid-based formulations: An opportunity to optimize performance for challenging therapeutics | ||
| 26.09. | Key exemptions could limit impact of Trump's pharmaceutical tariffs | ||
| 26.09. | Crinetics drug to challenge pharma 'Goliaths'; FDA, ARPA move to speed gene therapies | ||
| 25.09. | Lilly's oral SERD gets FDA nod in advanced breast cancer | ||
| 25.09. | Lilly stops trial of muscle-sparing obesity drug | ||
| 25.09. | Capricor readies revised FDA pitch for Duchenne cell therapy | ||
| 25.09. | Cancer patients are living longer than ever. Pain drugmakers haven't kept up. | ||
| 24.09. | UniQure to seek approval of Huntington's gene therapy after trial win | ||
| 24.09. | Acadia to scrap Prader-Willi drug after study setback | ||
| 24.09. | Sanofi Ventures banks $625M to back young biotechs, digital health startups | ||
| 23.09. | Disparity in vaccine access between states roils patients, providers | ||
| 23.09. | Bristol Myers says next-gen blood cancer drug hits goal in key study | ||
| 23.09. | FDA, in unusual step, aims to repurpose old GSK drug as autism treatment |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .